APUS Apimeds Pharmaceuticals US, Inc.
Pharmaceutical Preparations · NYSE · SEC CIK 1894525 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-341.0%
TTM EPS YoY-84.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-30.6%
ROA-27.9%
ROIC (approx.)-26.2%
Asset turnover—
Leverage & solvency
Liabilities / assets8.5%
Debt / equity0.00x
Current ratio0.83x
Interest coverage-4.35x
Cash quality & payout
Operating cash flow / net income0.52x
Accruals ratio-13.5%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 |
|---|---|---|---|
| Income statement | |||
| Revenue | — | — | — |
| R&D expense | $1.63M | — | $98,544 |
| SG&A expense | $10.28M | $1.28M | $648,892 |
| Operating income | -$11.91M | -$1.28M | -$747,436 |
| Interest expense | $283,011 | $117,719 | $38,069 |
| Net income | -$6.00M | -$1.39M | -$777,694 |
| EBITDA | -$11.91M | — | — |
| EPS (basic) | -0.55 | -0.18 | -0.17 |
| EPS (diluted) | -0.55 | -0.18 | -0.17 |
| Weighted avg. shares (diluted) | 10.88M | 7.90M | — |
| Banking | |||
| Deposits | $8.00M | — | — |
| Balance sheet | |||
| Cash & equivalents | $144,601 | $3,455 | $410,481 |
| Short-term investments | $2.00M | — | — |
| Current assets | $13.98M | $13,057 | $422,076 |
| PP&E, net | $51,626 | — | — |
| Total assets | $164.18M | $13,057 | $422,076 |
| Current liabilities | $10.71M | $1.02M | $123,316 |
| Total liabilities | $10.84M | $1.37M | $390,207 |
| Shareholders' equity | $153.35M | -$1.36M | $31,869 |
| Shares outstanding | 1.26M | 7.90M | 7.90M |
| Cash flow statement | |||
| Operating cash flow | -$8.93M | -$733,526 | -$627,790 |
| Capital expenditure | $57,333 | — | — |
| Free cash flow | -$8.98M | — | — |
| Investing cash flow | -$10.06M | — | — |
| Financing cash flow | $20.62M | $326,500 | $1.03M |
| Depreciation & amortization | $5,706 | — | — |
| Stock-based compensation | $1.57M | $69,993 | $69,993 |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.